<DOC>
	<DOCNO>NCT03013881</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics escalate single-dose UB-921 healthy male volunteer .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Pharmacokinetics UB-921 Healthy Volunteers</brief_title>
	<detailed_description>This open-label , two-part , dose-escalation comparative pharmacokinetics ( PK ) study UB-921 healthy male volunteer . Eligible volunteer sequentially enrol 3 escalating-dose cohort study site . After administration single-dose intravenous infusion UB-921 , subject follow 63 day monitor safety , tolerability , PK parameter .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Total body weight â‰§50 kg ( 110 lb ) No clinically relevant abnormality To agree use birth control barrier ( eg . male condom ) entire study period . Signing write informed consent form Previous exposure chimeric , humanize human monoclonal antibody , whether license investigational A history drug abuse heavy drinking . Blood donation 250 mL within 90 day prior screen Not condition participate study consider investigator ( )</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>UB-921</keyword>
	<keyword>anti-HER2 monoclonal antibody</keyword>
	<keyword>breast neoplasm</keyword>
	<keyword>breast cancer</keyword>
	<keyword>Herceptin</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>HER2</keyword>
</DOC>